EUCTR2006-003500-19-DE进行中（未招募）不适用
A multi-centre, randomised, double-blind, double-dummy,placebo-controlled, 3-way crossover, incomplete block designstudy to investigate the efficacy, safety, tolerability,pharmacodynamics and pharmacokinetics of three inhaled dosesof GSK233705 (10, 20 and 50mcg twice daily) administeredconcurrently with salmeterol 50mcg twice daily, and salmeterol50mcg twice daily alone, in subjects with chronic obstructivepulmonary disease (COPD)
GlaxoSmithKline Research and Development0 个研究点目标入组 45 人开始时间: 2006年8月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female subjects aged 40 – 75 y inclusive at the Screening visit.
- •2.Female subjects must be of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or double oophrectomy or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
- •3.Male subjects must agree to abstain from or use a condom during sexual intercourse with females of child-bearing potential; or if unwilling to use a condom/spermicide, their female partner must use another form of contraception, such as an IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants or a tubal ligation. This criterion must be followed from the time of the first dose of study medication until 84 days after the last dose of study medication.
- •4.An established clinical history of COPD at Screening Visit 2, in accordance with the following definition by the American Thoracic Society/European Respiratory Society (ATS/ERS) [Celli, 2004]
- •Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences.
- •5.Post-bronchodilator FEV1 of = 40% to = 75% of predicted normal at Screening Visit 2. Subjects who do not have FEV1 values within this range at Visit 2 may have a repeat assessment at Visit 2A to establish eligibility before randomisation (Visit 3). Subjects who do not have FEV1 values within this range will not be eligible for the study.
- •6.Subject has post-bronchodilator FEV1/FVC ratio = 70% at Screening Visit 2.
- •7.Subject must be responsive to ipratropium bromide defined as:
- •Either: an increase in FEV1 of = 12% and = 150 mL at 2 h following inhalation of 80 ?g of ipratropium bromide at the Pre-screening Visit 1,
- •or: a documented increase in FEV1 of = 12% and = 150 mL at 2 h following inhalation of 80 ?g of ipratropium bromide within 6 months of the pre-screening visit and an increase in FEV1 of >6% and >100 mL 2 h following inhalation of 80 ?g of ipratropium bromide at Pre-screening Visit 1 (in order to allow for potential fluctuations in the response to ipratropium bromide in patients known to be responders to ipratropium bromide).
- •Subjects who do not demonstrate the required increase in FEV1 in response to ipratropium at Visit 1 may have the assessment repeated once at Visit 1A, before randomisation (Visit 3),. Subjects who do not demonstrate the required increase in FEV1 at pre-screening are not eligible to enter the study.
- •8.Subjects must be responsive to salbutamol defined as:
- •Either: an increase in FEV1 of = 12% and = 150 mL at 30 mins following inhalation of 400 ?g of salbutamol at Screening Visit 2, or
- •or: a documented increase in FEV1 of = 12% and = 150 mL at 30 mins following inhalation of 400 ?g of salbutamol within 6 months of the screening visit and an increase in FEV1 of >6% and >100 mL 30 mins following inhalation of salbutamol 400 ?g at Screening Visit 2 (in order to allow for potential fluctuations in the response to salbutamol in patients known to be resp
排除标准
- •1.COPD exacerbation, or changes in COPD medication (other than use of relief VENTOLIN) within the 4 weeks prior to Screening Visit 2 or during the run-in period.
- •2.Received antibiotic therapy for either a lower respiratory tract infection or for COPD exacerbation within the 4 weeks prior to Screening Visit 2 or during the run-in period.
- •3.Hospitalised for a COPD exacerbation in the 6 months prior to Screening Visit 2 or during the run-in period.
- •4.Current diagnosis of asthma or a post-salbutamol increase in lung function of >500 mL at any reversibility assessment prior to randomisation (Visit 3).
- •5.Known respiratory disorders other than COPD (e.g., lung cancer, sarcoidosis, tuberculosis, bronchiectasis, lung fibrosis).
- •6.Medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the Investigator should prevent them from entering the study.
- •7.Undergone lung surgery (e.g., lung transplant and/or lung volume reduction) which in the opinion of the investigator may affect the outcome of the study.
- •8.Currently receiving pulmonary rehabilitation.
- •9.Had a chest X-ray indicating diagnosis other than COPD that might interfere with the study (in the 12 months prior to the screening visit).
- •10.Requires regular (daily) or long term oxygen therapy (LTOT).
- •11.Experienced two or more COPD exacerbations requiring treatment with oral, parenteral or depot corticosteroids in the last 6 months.
- •12.Received oral or parenteral corticosteroids within 4 weeks or depot corticosteroids within the 3 months prior to Screening Visit 2 or during the run-in period.
- •13.Receiving inhaled corticosteroids at a dose greater than 1000 ?g / day of fluticasone propionate (FP) or equivalent during the run-in period.
- •14.Currently receiving ß-blockers (except eye drops).
- •15.Any of the following cardiovascular criteria:
- •a.History of significant congestive heart failure (greater than New York Heart Association Type I), myocardial infarction, ischaemic heart disease requiring regular therapy with drugs other than nitrates or clinically significant cardiac arrhythmia.
- •b.Mean QTc(B) at screening of > 440 msec, the QTc(B) of all three screening ECGs at the screening visit are not within 10% of the mean, a PR interval outside the range 90-220 msec or an ECG that is not suitable for QT measurements (e.g., poorly defined termination of the T wave or left bundle branch block).
- •c.History of elevated supine blood pressure or mean blood pressures = 160/90 mmHg at Screening Visit 2 (except for hypertension which is well-controlled with thiazide medication only).
- •d.Mean heart rate outside the range 50–90 bpm at Screening.
- •16.Subjects who are not considered able to tolerate three 2-week wash-out periods according to the study schedule with all COPD medications removed apart from relief use of VENTOLIN via metered dose inhaler (MDI) or DISKUS/ACCUHALER (inhaled use as required) or inhaled corticosteroids at a dose less than 1000 ?g / day of fluticasone propionate (FP) or equivalent.
- •17.The subject has a positive drugs of abuse test at Screening Visit 2.
- •18.A positive alcohol test (breath or urine), including ethanol. The detection of alcohol would not be an exclusion at Screening but the subject would need to provide a negative test result pre-dose and during the study.
- •19.A suspected history of alcohol abuse within the 6 months prior to Screening.
- •20.The subject has tested positive for hepatitis C antibody, he
研究者
相似试验
进行中（未招募）
1 期
A multi-centre, randomised, double-blind, double-dummy,placebo-controlled, 3-way crossover, incomplete block designstudy to investigate the efficacy, safety, tolerability,pharmacodynamics and pharmacokinetics of three inhaled dosesof GSK233705 (10, 20 and 50mcg twice daily) administeredconcurrently with salmeterol 50mcg twice daily, and salmeterol50mcg twice daily alone, in subjects with chronic obstructivepulmonary disease (COPD)EUCTR2006-003500-19-NLGlaxoSmithKline Research and Development
进行中（未招募）
不适用
A multi-centre, randomised, double-blind, double-dummy,placebo-controlled, 3-way crossover, incomplete block designstudy to investigate the efficacy, safety, tolerability,pharmacodynamics and pharmacokinetics of three inhaled dosesof GSK233705 (10, 20 and 50mcg twice daily) administeredconcurrently with salmeterol 50mcg twice daily, and salmeterol50mcg twice daily alone, in subjects with chronic obstructivepulmonary disease (COPD)Study is in COPD patientsMedDRA version: 8.1Level: LLTClassification code 10010952Term: COPDEUCTR2006-003500-19-GBGlaxoSmithKline Research and Development
进行中（未招募）
不适用
A multi-centre, randomised, double-blind, double-dummy,placebo-controlled, 3-way crossover, incomplete block designstudy to investigate the efficacy, safety, tolerability,pharmacodynamics and pharmacokinetics of three inhaled dosesof GSK233705 (10, 20 and 50mcg twice daily) administeredconcurrently with salmeterol 50mcg twice daily, and salmeterol50mcg twice daily alone, in subjects with chronic obstructivepulmonary disease (COPD)Study is in COPD patientsMedDRA version: 8.1Level: LLTClassification code 10010952Term: COPDEUCTR2006-003500-19-FIGlaxoSmithKline Research and Development60
进行中（未招募）
不适用
A study to evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Indacaterol Maleate as a new formulation in the Concept1 deviceMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2011-001825-25-DEovartis Pharma Services AG36
进行中（未招募）
不适用
A study to evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Indacaterol Maleate as a new formulation in the Concept1 deviceAsthmaEUCTR2011-001825-25-GBovartis Pharma Services AG36